Jupiter Life Line Hospitals Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Labor Code provision drives PAT decline: A one-time ₹6.4 cr exceptional charge for the new Labor Code hit Q3 PBT, pushing 9M FY26 PAT down 3.1% YoY even as existing hospitals held steady operationally.
• Dombivli launch is the story now: The 500-bed greenfield hospital opens February 15, on time and on budget, but will drag consolidated EBITDA for roughly two years before breaking even.
• Mature assets are maxed out: Thane and Pune are near full utilization, so single-digit top-line growth is structural, not a demand problem; the entire ~10% revenue growth this quarter came from ARPOB.
• Indore is the bridge asset: Still in its growth phase with ~15% ARPOB expansion and newly added beds absorbing volume; management expects slightly higher growth and incremental margins over the next couple of years.
• What to watch next quarter: The initial occupancy ramp at Dombivli, the size of the depreciation step-up hitting the P&L, and any sign that Indore's growth is sustaining as guided.

Dombivli: The Next Growth Engine, and the Near-Term Drag

• Launch timeline: The 750,000 sq ft, 500-bed facility will be inaugurated February 15, ahead of its originally planned Q1 FY27 launch, with Phase 1 opening 200 clinical beds and further capacity added in phases as occupancy builds.
• Ramp-up philosophy: Management views the first three years as a stabilization and foundational maturity period, followed by a second three-year phase of rapid growth; the first year or two will lose money and create a consolidated EBITDA drag.
• First-year drag estimate: Based on past greenfield experience, management expects an average EBITDA loss of ₹2–3 cr per month in year one, though the actual number for Dombivli remains to be seen.
• Breakeven target: The hospital is expected to reach EBITDA breakeven by the end of year two.
• Specialty mix and ARPOB: The hospital will offer the full spectrum from childbirth to transplantation, identical to all other Jupiter hospitals; ARPOB will start lower, reflecting more primary and secondary work initially, then converge toward Thane levels as the hospital matures.
• Location thesis: The site was chosen for a micro-market with very high resident population and relatively low supply of high-end tertiary care services nearby.

Thakker: "The 750,000 square foot 500-bed structure has been completed before time and on budget, ahead of its planned launch in Q1 of FY '27."

Mature Assets: Full, Steady, and Inflation-Linked

• Capacity ceiling: Thane has little ability to generate more occupancy growth, and the Pune opportunity is narrowing; management says it hopes mature hospitals report zero growth because they are already at maturity.
• ARPOB as the sole growth lever: The entire ~10% revenue growth this quarter was attributed to ARPOB increase, from approximately ₹59,000+ to ₹66,000; mature asset ARPOB is expected to grow in line with inflation going forward.
• Margin profile: Two of the three operating hospitals are near maturity and should have similar margins; the company does not break out individual hospital margins but confirms this parity.
• Full-service model: All hospitals practice every branch of medicine; management explicitly avoids narrow specialty focus, believing broad-spectrum capability is core to the model.
• No payer friction: Services remain largely uninterrupted across almost all payers, with no unusual friction reported with the payer community.

Thakker: "We think that this ARPOB number is more of a byproduct of what you do. We are not looking at or chasing any specific ARPOB number."

Indore: The Bridge to the Next Wave

• Growth phase continues: Indore added 78 beds last year and is utilizing them, with occupancy higher in absolute terms this year; management sees opportunity for higher growth over the next couple of years.
• ARPOB running hot: Indore ARPOB grew ~15%, driven by both inflation and its maturity phase; newer hospitals grow ARPOB faster in the first ~6 years before converging to inflation-linked growth.
• Margin trajectory: Slightly incremental margins are expected over the next couple of years as the hospital progresses toward maturity.
• Blended ARPOB outlook: Over the next 1–3 years, Dombivli will dilute the blended ARPOB, Indore will grow a little faster than inflation, and Thane and Pune will track inflation.

Pipeline: Pune South and Beyond

• Pune South (Bibvewadi): Basement work is complete and excavation is finished; the project is slated to begin operations in calendar year 2028, and management is reasonably sure of achieving that target.
• Mira Road: The project is currently under the regulatory approval process; no timeline was provided.
• Seventh hospital: Management may consider adding a seventh hospital, but there is no update on location or timing.
• Long-term strategy: Over the next decade, the plan is simply to keep participating in supply growth by building more hospitals.

Thakker: "There is nothing else I know how to do. So we'll have to keep doing this."

Costs, Margins, and the Questions Management Won't Answer

• Doctor cost range: Management says doctor costs typically run 20–25% of top line and the company has generally been in that range, though it declined to provide quantitative numbers for the past 2–3 years.
• Doctor retention: No impact from a competitor adding a hospital in the region; only one full-time doctor moved, which management characterizes as zero attrition.
• Compensation philosophy: Management believes long-term sustainability requires paying in line with industry standards: significantly above is inefficient, significantly below risks continual attrition and unstable teams.
• Depreciation step-up: Beginning next quarter, a much higher depreciation load will appear on consolidated numbers as Dombivli is capitalized.
• Long-term margin question deflected: When asked whether costs (nurses, doctors) rising faster than inflation-linked ARPOB could compress margins long-term, management declined to answer substantively, calling the question too complex for the call.
• Insurance renewal pricing: Negotiated at each renewal and linked to inflation; cannot be quantified in advance.
• Government scheme exposure: Only 1% of revenue comes from government schemes, limited to radiation treatment for cancer and congenital heart disease for children, treated as a social contribution.

Thakker: "Too much of astrology is difficult to do. I'm sorry, but I really don't have too many answers about this."

Guidance & Commitments

Key Metrics